Aardvark Therapeutics
- 10/05/2024
- Series C
- $85,000,000
San Diego based pharmaceutical company specializing in gut brain interaction with a focus of inflammation and metabolism
- Industry Pharmaceutical Manufacturing
- Website https://aardvarktherapeutics.com/
- LinkedIn https://www.linkedin.com/company/aardvark-therapeutics/
Related People
Tien LeeFounder
Dr. Lee has over 15 years of experience as a biotechnology innovator and executive who has been integrally involved with the founding or advancement of several biopharmaceutical companies. Since 2017, Dr Lee is the founder/CEO of Aardvark Therapeutics, Inc. Prior to this, Dr. Lee joined Nantkwest in 2014 and served as its Chief Strategy Officer until March, 2017. His experience includes therapeutics for immunology, cardiovascular, oncology, neurology, and infectious disease indications. Dr. Lee is also an inventor or co-inventor of multiple biomedical and biotechnology innovations, licensed or assigned to several companies for development including Nantkwest (Nasdaq: NK), Simcere Pharmaceutical Group, Cellics Therapeutics, Sorrento Therapeutics (Nasdaq: SRNE), and Aardvark Therapeutics. Dr. Lee earned his M.D. degree from UC San Diego and his B.A. degree from UC Berkeley in Molecular Biology where he was also a Regents and Alumni Scholar. Dr. Lee received post-graduate training in Internal Medicine through UC Los Angeles and Physical Medicine and Rehabilitation at UC Irvine.